Show Summary Details
Page of

Cost Utility of Atypical Antipsychotics: CUtLASS-1 

Cost Utility of Atypical Antipsychotics: CUtLASS-1
Cost Utility of Atypical Antipsychotics: CUtLASS-1

Nikhil Gupta

, and John Cahill

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 October 2019

This chapter provides a summary of a landmark study on schizophrenia. Are second-generation antipsychotics (SGAs) better than first-generation antipsychotics (FGAs) for individuals with schizophrenia needing an antipsychotic change? Additionally, are there improvements in quality of life and savings in health service use to justify the additional costs of SGAs over FGAs? Starting with these questions, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chapter briefly reviews other relevant studies and information, discusses implications, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.